

Characterization of resistance mechanisms of *Enterobacter cloacae* Complex Co-resistant to Carbapenem and Colistin

Tieli Zhou (✉ wyztli@163.com)

Wenzhou Medical University First Affiliated Hospital <https://orcid.org/0000-0002-2171-4710>

Shixing Liu

Wenzhou Medical University First Affiliated Hospital

Renchi Fang

Zhejiang University School of Medicine First Affiliated Hospital

Ying Zhang

Wenzhou Medical University School of Laboratory Medicine and Life Sciences

Lijiang Chen

Wenzhou Medical University First Affiliated Hospital

Na Huang

Wenzhou Medical University First Affiliated Hospital

Kaihang Yu

Wenzhou Medical University School of Laboratory Medicine and Life Sciences

Cui Zhou

Wenzhou Medical University First Affiliated Hospital

Jianming Cao

Wenzhou Medical University School of Laboratory Medicine and Life Sciences

Research article

Keywords: enterobacter cloacae complex, carbapenem, colistin, co-resistance

Posted Date: June 30th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-38056/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Microbiology on July 8th, 2021. See the published version at <https://doi.org/10.1186/s12866-021-02250-x>.

Abstract

Background: The emergence of carbapenem-resistant and colistin-resistant ECC pose a huge challenge to infection control. The purpose of this study was to clarify the mechanism of the carbapenems and colistin co-resistance in *Enterobacter cloacae* Complex (ECC) strains.

Methods: Nineteen ECC isolates co-resistant to carbapenems and colistin were collected from a regional medical center in China. Carbapenemase gene, extended-spectrum β -lactamase gene, AmpC cephalosporinase gene *ampC*, *mcr* series genes, and *ecr* gene were detected by PCR. Expression levels of outer membrane protein OmpC/OmpF and efflux pump protein AcrA/AcrB were investigated. And the structural modification of lipid A of 19 ECC strains was analyzed.

Results: This study showed that the mechanisms of carbapenem resistance in this study are: 1. Generating carbapenemase (7 of 19); 2. The production of AmpC or ESBLs combined with decreased expression of out membrane protein (12 of 19). And the mechanism of colistin resistance is increasing expression of *acrA* in the efflux pump AcrAB-TolC alone (5 of 19) or accompanied by a decrease of affinity between colistin and outer membrane caused by the modification of lipid A (14 of 19). Moreover, an ECC strain co-harboring plasmid-mediated *mcr-4.3* and *blaNDM-1* has been found.

Conclusions: This study suggested that there is no overlap between the resistance mechanism of co-resistant ECC strains to carbapenem and colistin. However, the emergence of strain co-harboring plasmid-mediated resistance genes indicated that ECC is a potential carrier for the horizontal spread of carbapenems and colistin resistance.

Background

Enterobacter cloacae complex (ECC) belongs to the *Enterobacter* genus of the *Enterobacteriaceae* family, which exists widely in nature and is also part of the common bacterial flora of the human gastrointestinal tract. In the past few decades, ECC was one of the most common pathogens in hospitals, often causing various infections, such as pneumonia, urinary tract infections, and sepsis (1). *Enterobacter cloacae* and *Enterobacter hormaechei* are the most common in clinical infected patients, especially in patients with immunocompromise and who admitted to the intensive care unit (ICU) (2). Due to the widespread use of antibiotics and the ability of ECC to be good at up-regulating or obtaining drug resistance determinants, multi-drug resistance (MDR) ECC strains have emerged and spread around the world. ECC infection accounts for 65% -75% of *Enterobacter* infections, which was called "ESKAPE" pathogen with five other common pathogens (*Enterococcus faecalis*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*) (3, 4).

ECC is intrinsically resistant to penicillins and first- and second-generation cephalosporins due to low-level expression of chromosomal *ampC* genes which encoding an inducible AmpC-type cephalosporinase (5). When ECC is exposed to β -lactam drugs for a long period of time, it can further lead to the highly induced phenotypes of AmpC cephalosporin, thus producing resistance to third-generation

cephalosporins (6). The most common mechanism is that *ampD* mutation leads to structural overexpression of AmpC (7). At the same time, several studies have shown that mutations in the *ampR* gene, although relatively rare, can also cause overexpression of AmpC (8, 9). In addition, the acquisition of a variety of plasmids mediated extended-spectrum β -lactamase (ESBL) genes conferred ECC resistance to most β -lactam drugs, making the treatment more difficult. Because ECC strains that overexpress AmpC enzymes and produce ESBLs were usually susceptible to carbapenem, carbapenem were considered to be the preferred antibacterial for the treatment of infections caused by high levels of cephalosporin-resistant ECC. The emergence of carbapenem-resistant ECC has aroused great clinical attention. Literature has shown that the resistance of *Enterobacter cloacae* to carbapenem can be mediated by AmpC expression and membrane permeability changes, but it may be more common to obtain carbapenemase gene transferred by plasmids (10). The plasmid-mediated mechanism significantly increases the spread of carbapenem resistance, while further limiting the choice of effective antibacterial drugs.

However, a number of recent studies have found that ECC strains carry carbapenemase genes while being resistant to colistin (11-13). Colistin is an old antibiotic which has been refocused in recent years. Because of the good activity against Gram-negative bacteria, it is considered to be one of the last-line antimicrobials for treatment of MDR Gram-negative bacteria (14). According to previous reports, ECC may acquire colistin resistance by plasmid-mediated gene *mcr*, small protein gene *ecr* or two-component systems *phoPQ*, *pmrAB* (13, 15, 16). The emergence of carbapenem-resistant and colistin-resistant ECC will undoubtedly pose a huge challenge to infection control. And the mechanism of carbapenem and colistin resistance mediated by movable elements also increases the risk of widespread transmission.

The purpose of this study is to clarify the mechanism of the carbapenems and colistin co-resistance in ECC strains. We collected co-resistant ECC clinical isolates from a regional medical center, and performed this study through methods such as phenotype testing, gene identification, relative expression detection, and mass spectrometry analysis in order to provide further understanding for the resistance development of ECC strains.

Results

Results of antimicrobial susceptibility testing and efflux inhibitors assay

Antimicrobial susceptibility testing was used to determine the minimum inhibitory concentrations (MICs) of Carbapenem and Colistin. As shown in table S2, all 19 ECC strains were resistant to ertapenem ($MIC_{50} = 4 \mu\text{g/mL}$) and colistin ($MIC_{50} = > 64 \mu\text{g/mL}$). Besides, 5 ECC strains were resistant to meropenem, 6 ECC strains were resistant to imipenem, and 4 of them were resistant to 3 carbapenems. The results obtained from the efflux inhibitors assay were shown in Figure 1. In the presence of efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP), the MICs of colistin to 19 ECC strains decreased significantly and returned to susceptible, while CCCP showed no effect on the MICs of ertapenem. Taken together,

these results suggest that there is an association between colistin resistance of ECC strains and efflux pump.

Prevalence of carbapenemase, ESBLs and AmpC cephalosporinase

As summarized in Figure 1, 7 ECC strains were positive in modified carbapenem inactivation methods (mCIM), indicating that they are carbapenemase-producing strains (figure 1). Further identified the types of carbapenemase genes carried by these 7 ECC strains, including 3/19 (15.8%) *bla*_{KPC-2} gene and 4/19 (21.1%) *bla*_{NDM-1} gene. In addition to carbapenemase encoding genes, ESBL genes were detected in 11 of 19 ECC strains, with *bla*_{CTX-M-14} the most prevalent (n=8, 42.1%), followed by *bla*_{CTX-M-9} (n=6, 31.6%), *bla*_{SHV} (n=6, 31.6%), *bla*_{TEM} (n=3, 15.8%), *bla*_{CTX-M-1} (n=3, 15.8%) (Figure 1). AmpC cephalosporinase gene *ampC* were detected in all 19 ECC strains (Figure 1).

Relative expression of genes encoding outer membrane protein and efflux pump protein

To assess the relationship between carbapenem resistance and the expression of outer membrane proteins OmpC and OmpF and the relationship between colistin resistance and expression of efflux pump proteins AcrA and AcrB, 19 ECC strains co-resistant to carbapenem and colistin, 1 carbapenem and colistin co-susceptible ECC strain CG37 and *Enterobacter cloacae* ATCC 700323 were used. As shown in Figure 2, compared with ATCC 700323, the expression level of *ompC* was reduced in 15 co-resistant ECC strains. Furthermore, the expression of *ompF* was deficient in all 19 co-resistant ECC strains. The efflux pump gene *acrA* was found to be significantly overexpressed in 18 co-resistant ECC strains. Conversely, the *acrB* gene was not found to be significantly overexpressed in co-resistant ECC strains (except CG1249).

Prevalence of *mcr*, *ecr* genes and structural modification of wild-type lipid A

To investigate whether the colistin resistance of the ECC strains in this study is related to the modification of lipid A, we detected the relevant resistance genes and analyzed the ion peak spectrum of lipid A using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS). From Figure 1 we can see that the ECC strain CG175 harboring *mcr-4.3*, which belongs to the plasmid-mediated *mcr* family gene. Moreover, a novel transmembrane protein gene *ecr* was found in other 11 ECC strains (Y541, CG737, CG741, CG701, CG864, CG884, CG934, CG1038, CG1050, CG1051, CG1506). The structures of lipid A in ECC strains in this study showed diversity (Figure 3 and Figure 4). Among them, colistin-susceptible ATCC 700323 possessed wild-type lipid A with three ion peaks of *m/z* 1796, 1824, and 2062, respectively (Figure 3A). Wild-type lipid A were also present in 19 co-resistant ECC strains, of which the ion peak of *m/z* 1824 is predominant. Interestingly, 14 of the 19 ECC strains contained modified lipid A related to colistin resistance. Taken together, the ion peak spectrum of 14 co-resistant ECC strains can be divided into 3 different modes (Figure 3B, Figure 3C, Figure 3D), including 4 ion peaks of *m/z* 1919, 1947, 1955, and 2185. From the data in Figure 4, the groups that modify wild-type lipid A and cause resistance to colistin are phosphoethanolamine (pETN, *m/z* 123) and 4-amino-4-deoxy-L-arabinose (-L-Ara4N, *m/z* 131).

Discussion

ECC can adapt to the environment quickly and obtain resistance to various antibacterial drugs by inducing resistance determinants and gaining exogenous resistance genes. The emergence of MDR ECC poses a huge challenge for the effective clinical treatment.

Carbapenem is an atypical β -lactam antibiotic with the broadest resistance spectrum and has the best antibacterial effects at present. It also maintains good susceptibility to *Enterobacteriaceae* carrying ESBLs or overexpressing AmpC-type cephalosporinase, and is the choice for clinical control of MDR ECC infections (17, 18). However, with the widespread use of carbapenem, the number of carbapenem-resistant ECC clinical strains is increasing, which can lead to failure of clinical anti-infection treatment. As mentioned in the literature review, the main mechanisms that mediate the resistance of ECC strains to carbapenem are: 1. Generating carbapenemase ; 2. The production of AmpC or ESBLs combined with loss or decreased expression of outer membrane protein (19, 20). In addition, studies have found that the susceptibility of *Escherichia coli* and *Enterobacter cloacae* to carbapenem can be increased when the AcrAB-TolC efflux pump is inhibited (21, 22).

Colistin is an "old" antibiotic, which has been re-applied to the clinic because of its good antibacterial activity against MDR gram-negative bacteria. In fact, it is the last line of drug for the treatment of serious infections caused by MDR gram-negative bacteria. As reported by Mirelis, the total resistance rate of *Enterobacteriaceae* to colistin was 0.67% but the resistance rate of *Enterobacter cloacae* 4.2% was much higher than that of *Escherichia coli* and *Klebsiella pneumoniae* (23). The resistance mechanism of ECC strains to colistin can be mediated by the *mcr-1* gene carried by the plasmid (15, 24, 25), and may also be related to the mutations of two-component system encoded by *pmrAB* and *phoPQ* (13). Recently, Zong *et al.* found that a novel small transmembrane protein Ecr may mediate the heterogeneous resistance of ECC to colistin through the PhoPQ two-component system (16), but the distribution of *ecr* gene in ECC strains and its correlation with colistin resistance still need further study. In reviewing the literature, colistin resistance mediated by *mcr* series genes or mutations in *pmrAB* and *phoPQ* is related to structural modification of lipid A of ECC strains, such as phosphoethanolamine (pETN) or 4-amino-4-deoxy-L-arabinose (-L-Ara4N). The modification of wild-type lipid A can reduce the potential of the outer membrane in *Escherichia coli* and reduce the affinity of colistin to the outer membrane (26, 27). Furthermore, the overexpression of efflux pump AcrAB-TolC may also lead to the resistance of ECC strains to colistin (28). In recent years, carbapenems and colistin co-resistant ECC strains have been found in multiple regions around the world (11-13, 29-31), which will further increase the difficulty of treating MDR ECC infection. And some of the co-resistant ECC strains have the ability to spread drug resistance gene horizontally, which posing a huge threat to public health.

The current study found that 7 out of 19 carbapenems and colistin co-resistant ECC strains carried the carbapenemase gene, of which 3 strains carried *bla*_{KPC-2} and 4 strains carried *bla*_{NDM-1}. It can be found that the ECC strains carrying the carbapenemase gene are all resistant or intermediary to meropenem, imipenem, and ertapenem, but most of the ECC strains that do not carry the carbapenemase gene were

only resistant to ertapenem in a low level, and were susceptible to meropenem and imipenem. This finding is in agreement with CLSI guidelines which suggested that resistance of *E. cloacae* to imipenem and meropenem is usually related to the carbapenemase gene (32). This study found that the predominant mechanism of carbapenem resistance in ECC strains is not generating carbapenemase. The results of this study showed that AmpC or ESBLs production combined with decreased expression of outer membrane protein confer low-level resistance to ertapenem in ECC strains that do not produce carbapenemase. In addition, no correlation was found between the efflux pump AcrAB-TolC and carbapenem resistance of ECC strains in this study.

This study found that 11 (57.9%) of the 19 ECC strains carry the *ecr* gene, which is thought to be related to colistin heterogeneity resistance by regulating lipid A modification. Further analysis of lipid A by MALDI-TOF mass spectrometry revealed that all ECC strains carrying the *ecr* gene undergo lipid A modification, suggesting that *ecr* may mediate colistin resistance in this study. Interestingly, of the 11 strains carrying the *ecr* gene, except for the wild-type lipid A of Y541, which was modified with phosphoethanolamine (pETN), and the remaining strains were all modified with 4-amino-4-deoxy-L-arabinose (-L-Ara4N). We speculate that Y541 may be involved in other colistin resistance mechanisms, which need further study. The results of the efflux inhibitor assay suggest that colistin resistance may also be related to the efflux pump, and the expression of the efflux pump genes *acrB* showed that except for the strain CG741, the expression levels of *acrB* in other ECC strains did not increase significantly. However, the expression levels of *acrA* gene in 18 ECC strains increased in varying degrees. This result is different from *et al.*'s report that the regulation of *sosRS* can simultaneously upregulate expression of *acrA* and *acrB* to induce heterogeneous resistance in *Enterobacter cloacae*. This inconsistency may be due to *acrA*, *acrB* and *tolC* genes are not co-regulatory genes. Their expression is usually regulated by multiple levels of different regulatory factors (33-35).

Notably, CG175 carries the *bla*_{NDM-1} gene along with the *mcr-4.3* gene. The genomic characteristics of this strain have been reported in the study of Chavda *et al.* (12). This is the first *Enterobacter cloacae* isolate co-harboring *mcr-4.3* and *bla*_{NDM-1} that reported in China. Although in the study by Chavda *et al.*, it was found that *mcr-4.3* and *bla*_{NDM-1} were present in two separate plasmids (ColE plasmid and IncX3 plasmid) and *mcr-4.3* did not mediate colistin resistance. However, the emergence of this strain has sounded the alarm for clinical anti-infection treatment. Because ECC strains are widely distributed in the hospital environment, are potential carrier of mobile resistance genes.

Conclusion

In summary, the main mechanisms of carbapenem resistance in this study are: 1. Generating carbapenemase; 2. The production of AmpC or ESBLs combined with decreased expression of outer membrane protein. And the mechanism of colistin resistance is the increase of *acrA* in the efflux pump AcrAB-TolC alone or accompanied by a decrease of affinity between colistin and outer membrane caused by the modification of lipid A.

Materials And Methods

Clinical isolates

Nineteen ECC isolates co-resistant to carbapenem and colistin were collected from the First Affiliated Hospital of Wenzhou Medical University in China, from 2011 to 2018. All isolates were identified by MALDI-TOF MS using a VITEK[®] mass spectrometer (BioMerieux, Lyons, France).

Antimicrobial susceptibility testing

The MICs of carbapenems (meropenem, imipenem, and ertapenem) and colistin to the 19 ECC strains were performed by the agar dilution method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) guidelines (32). And the breakpoint of carbapenem and colistin for ECC was interpreted according to the guidelines of CLSI (32) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (36) respectively. *Escherichia coli* ATCC 25922 was used as a control strain in this study.

mCIM test

To screen for suspected carbapenemase production in the 19 ECC strains, the mCIM was performed. As recommended by CLSI(32), emulsify a 1 μ L loopful of bacteria from an overnight blood agar plate in 2 mL trypsin soy broth (TSB). Add a 10- μ g meropenem disk in each suspension using sterile forceps and incubate at 35°C \pm 2°C in ambient air for 4 h \pm 15 min. Remove the meropenem disk from each TSB-meropenem disk suspension and place it on the Mueller-Hinton agar (MHA) plate previously inoculated with the meropenem-susceptible *E. coli* ATCC 25922 indicator strain. Invert and incubate the MHA plates at 35°C \pm 2°C in ambient air for 18-24 h. Carbapenemase positive when the antibacterial zone diameter of 6-15 mm or presence of pinpoint colonies within a 16-18 mm zone; Carbapenemase negative when the antibacterial zone diameter of \geq 19 mm (clear zone).

Polymerase chain reaction (PCR) detection for resistance genes

The genomic DNA of the 19 ECC strains were extracted using the Biospin Bacterial Genomic DNA Extraction kit (Bioflux, Tokyo, Japan). Using these DNA templates we detected the carbapenemase gene (*bla*_{KPC}, *bla*_{NDM}, *bla*_{IMP}, *bla*_{VIM}, *bla*_{IMI}, *bla*_{SPM}, *bla*_{OXA-23}, *bla*_{OXA-24}, *bla*_{OXA-48}, *bla*_{OXA-58}, *bla*_{Nmc-A}, *bla*_{FRI-1}, *bla*_{BIC}, *bla*_{GIM}, *bla*_{SME}, *bla*_{AIM}, *bla*_{DIM}, *bla*_{SIM} and *bla*_{GES}), extended-spectrum β -lactamase gene (*bla*_{SHV}, *bla*_{TEM}, *bla*_{CTX-M-1}, *bla*_{CTX-M-9} and *bla*_{CTX-M-14}), AmpC cephalosporinase gene *ampC*, colistin resistance-related genes (*mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5* and *ecr*). The primers used for PCR amplification were showed in table S1. The positive PCR products were sequenced by Shanghai Genomics Institute Technology Co. Ltd (Shanghai, China). And the sequences of the product were analyzed by BLAST searches against the NCBI database (www.ncbi.nlm.nih.gov/BLAST).

Efflux inhibitors assay

In order to detect whether the efflux pump has an effect on drug resistance, MICs of ertapenem and colistin were determined in the presence or absence of efflux pump inhibitor: CCCP (8 µg/L, 1/4 MIC). CCCP stock solution uses dimethyl sulfoxide (DMSO) as the solvent. When the efflux pump inhibitors were present, a reduction of at least four-fold in the MICs were considered indicative of efflux(37).

Quantitative real-time PCR for outer membrane protein and efflux pump

Total RNAs of 19 ECC strains were extracted using the Bacterial RNA Miniprep Kit (Biomiga, Shanghai, China) according to the manufacturer's instructions. Then, 500 ng of RNA were mixed with the reverse transcription system of the PrimeScript™ RT reagent Kit (Takara, Japan) to obtain 10 µL of cDNA. The expression levels of outer membrane gene (*ompC*, *ompF*) and efflux pump gene (*acrA*, *acrB*) were performed by quantitative real-time PCR. The *rpoB* gene was selected as the internal gene. And the relative expression levels of four genes in 19 ECC strains were compared with the expression levels in co-susceptible *Enterobacter cloacae* ATCC 700323 and clinical strains CG37.

qPCR was performed using a CFX-96 touch™ Real-Time PCR system (Bio-Rad, California, USA) and TB Green Premix Ex Taq II (Tli RNaseH Plus) (2×) (Takara, Japan) with the specific primers (refer to Table S1). Then, 100 ng of cDNA was added to each sample as the template. Cycling conditions were as follows: 95°C for 30 s followed by 40 cycles of 9°C for 5 s and 60°C for 20 s. A melting curve was performed after each run (raising 0.5°C per second, from 65°C to 95°C). Each sample was run in triplicate and the means of Ct values were used for analysis. Quantification of the target genes was analyzed using the comparative threshold cycle $2^{-\Delta\Delta Ct}$ method. All experiments were repeated in triplicate independently.

Lipid A characterization by MALDI-TOF MS

Lipid A was isolated by using an optimized large-scale protocol based on mild acid hydrolysis (38). Overnight cultures (200 ml at 37°C) in LB broth were harvested by centrifugation at 3,220 × *g* for 30 min. Bacterial pellets were washed with single-phase Bligh-Dyer mixture (chloroform/methanol/water, 1:2:0.8 [vol/vol]) and centrifuged at 3,220 × *g* for 15 min. The LPS pellets were suspended in sodium acetate buffer (50 mM [pH 4.5]) and incubated at 100°C for 30 to 45 min. Reactions were moved into a two-phase Bligh-Dyer mixture (chloroform/methanol/water, 1:1:0.9 [vol/vol]) and centrifuged at 3,220 × *g* for 15 min. The lower phases were removed to clean tubes and dried using rotary evaporation. The dried samples contained whole-cell extracts of lipid A.

Dried lipid A samples were resuspended in 100 µl chloroform/methanol (1:1 [vol/vol]), and 3 µl 2,5-dihydroxybenzoic acid (DHB) matrix (20 mg/ml in TA30 solvent) was mixed with 3 µl lipid A. Aliquots of the mixture were spotted directly onto the well of the MALDI-TOF MS plate (ground steel). Mass spectra were recorded for optimal ion signals in negative-ion mode using a Bruker autoflex MALDI-TOF mass spectrometer (Bruker Daltonics Inc., Billerica, MA, USA). Data were acquired and processed by flexControl and flexAnalysis 3.4 (Bruker Daltonics Inc.).

Abbreviations

ECC: *Enterobacter cloacae* complex

PCR: Polymerase chain reaction

ICU: intensive care unit

MDR: multi-drug resistance

ESKAPE: *Enterococcus faecalis*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*

ESBL: extended-spectrum β -lactamase

MIC: minimum inhibitory concentrations

CCCP: carbonyl cyanide m-chlorophenylhydrazone ()

MALDI-TOF MS: matrix-assisted laser desorption/ionization time of flight mass spectrometry

CLSI: Clinical and Laboratory Standards Institute

EUCAST: European Committee on Antimicrobial Susceptibility Testing ()

mCIM: modified carbapenem inactivation methods

qPCR: Quantitative real-time PCR

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Planned Science and Technology Project of Wenzhou (no. Y20170204). The funding body provided funds for the purchase of consumption materials for the study but had no role in the design of the study and collection, analysis, and interpretation of data and writing of the manuscript.

Authors' contributions

SXL and RCF contributed equally to this study. SXL and RCF wrote the manuscript under supervision of TLZ, JMC. SXL, RCF, YZ, LJC, NH, KHY and CZ performed the research. SXL and RCF performed the data analysis. The research plan for this project was conceived based on several rounds of discussions among all co-authors. All authors read and approved the final version of the manuscript.

Acknowledgements

This work was supported by the Planned Science and Technology Project of Wenzhou (no. Y20170204).

References

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. *Clin Infect Dis*. 2004;39(3):309-17.
2. Davin-Regli A, Lavigne JP, Pages JM. *Enterobacter* spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. *Clin Microbiol Rev*. 2019;32(4).
3. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J Infect Dis*. 2008;197(8):1079-81.
4. Sanders WE, Jr., Sanders CC. *Enterobacter* spp.: pathogens poised to flourish at the turn of the century. *Clin Microbiol Rev*. 1997;10(2):220-41.
5. Seeberg AH, Tolxdorff-Neutzling RM, Wiedemann B. Chromosomal beta-lactamases of *Enterobacter cloacae* are responsible for resistance to third-generation cephalosporins. *Antimicrob Agents Chemother*. 1983;23(6):918-25.
6. Babouee Flury B, Ellington MJ, Hopkins KL, Turton JF, Doumith M, Woodford N. The differential importance of mutations within AmpD in cephalosporin resistance of *Enterobacter aerogenes* and *Enterobacter cloacae*. *International journal of antimicrobial agents*. 2016;48(5):555-8.
7. Schmidtke AJ, Hanson ND. Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance. *Antimicrob Agents Chemother*. 2006;50(6):2030-7.
8. Kaneko K, Okamoto R, Nakano R, Kawakami S, Inoue M. Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of *Enterobacter cloacae*. *J Clin Microbiol*. 2005;43(6):2955-8.

9. Kuga A, Okamoto R, Inoue M. ampR gene mutations that greatly increase class C beta-lactamase activity in *Enterobacter cloacae*. *Antimicrob Agents Chemother*. 2000;44(3):561-7.
10. Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. Multidrug-Resistant *Enterobacter cloacae* Complex Emerging as a Global, Diversifying Threat. *Front Microbiol*. 2019;10:44.
11. Tarumoto N, Kodana M, Watanabe N, Sakai J, Imai K, Yamaguchi T, et al. First report of the isolation of bla_{IMI-1}-producing colistin-heteroresistant *Enterobacter cloacae* in Japan, September 2016. *J Infect Chemother*. 2018;24(11):941-3.
12. Chavda B, Lv J, Hou M, Chavda KD, Kreiswirth BN, Feng Y, et al. Coidentification of mcr-4.3 and bla_{NDM-1} in a Clinical *Enterobacter cloacae* Isolate from China. *Antimicrob Agents Chemother*. 2018;62(10).
13. Uechi K, Tada T, Shimada K, Nakasone I, Kirikae T, Fujita J. Emergence of a carbapenem-resistant and colistin-heteroresistant *Enterobacter cloacae* clinical isolate in Japan. *J Infect Chemother*. 2019;25(4):285-8.
14. Srinivas P, Rivard K. Polymyxin Resistance in Gram-negative Pathogens. *Curr Infect Dis Rep*. 2017;19(11):38.
15. Baron S, Bardet L, Dubourg G, Fichaux M, Rolain JM. mcr-1 plasmid-mediated colistin resistance gene detection in an *Enterobacter cloacae* clinical isolate in France. *J Glob Antimicrob Resist*. 2017;10:35-6.
16. Huang L, Feng Y, Zong Z. Heterogeneous resistance to colistin in *Enterobacter cloacae* complex due to a new small transmembrane protein. *The Journal of antimicrobial chemotherapy*. 2019;74(9):2551-8.
17. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2000;6(9):460-3.
18. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. *The Journal of antimicrobial chemotherapy*. 2003;52(4):538-42.
19. Chmelnitsky I, Navon-Venezia S, Strahilevitz J, Carmeli Y. Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible *Enterobacter cloacae* isolates. *Antimicrob Agents Chemother*. 2008;52(8):2962-5.
20. Chung HS, Yong D, Lee M. Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital. *J Investig Med*. 2016;64(5):1042-9.
21. Rosa JF, Rizek C, Marchi AP, Guimaraes T, Miranda L, Carrilho C, et al. Clonality, outer-membrane proteins profile and efflux pump in KPC- producing *Enterobacter* sp. in Brazil. *BMC microbiology*. 2017;17(1):69.
22. Chiu SK, Ma L, Chan MC, Lin YT, Fung CP, Wu TL, et al. Carbapenem Nonsusceptible *Klebsiella pneumoniae* in Taiwan: Dissemination and Increasing Resistance of Carbapenemase Producers During 2012-2015. *Sci Rep*. 2018;8(1):8468.

23. Prim N, Turbau M, Rivera A, Rodriguez-Navarro J, Coll P, Mirelis B. Prevalence of colistin resistance in clinical isolates of Enterobacteriaceae: A four-year cross-sectional study. *J Infect.* 2017;75(6):493-8.
24. Fournier C, Aires-de-Sousa M, Nordmann P, Poirel L. Occurrence of CTX-M-15- and MCR-1-producing Enterobacteriales in pigs in Portugal: Evidence of direct links with antibiotic selective pressure. *International journal of antimicrobial agents.* 2020;55(2):105802.
25. Zeng KJ, Doi Y, Patil S, Huang X, Tian GB. Emergence of the Plasmid-Mediated mcr-1 Gene in Colistin-Resistant *Enterobacter aerogenes* and *Enterobacter cloacae*. *Antimicrob Agents Chemother.* 2016;60(6):3862-3.
26. Son SJ, Huang R, Squire CJ, Leung IKH. MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance. *Drug Discov Today.* 2019;24(1):206-16.
27. Quesada A, Porrero MC, Tellez S, Palomo G, Garcia M, Dominguez L. Polymorphism of genes encoding PmrAB in colistin-resistant strains of *Escherichia coli* and *Salmonella enterica* isolated from poultry and swine. *The Journal of antimicrobial chemotherapy.* 2015;70(1):71-4.
28. Telke AA, Olaitan AO, Morand S, Rolain JM. soxRS induces colistin hetero-resistance in *Enterobacter asburiae* and *Enterobacter cloacae* by regulating the acrAB-tolC efflux pump. *The Journal of antimicrobial chemotherapy.* 2017;72(10):2715-21.
29. Huang L, Wang X, Feng Y, Xie Y, Xie L, Zong Z. First identification of an IMI-1 carbapenemase-producing colistin-resistant *Enterobacter cloacae* in China. *Ann Clin Microbiol Antimicrob.* 2015;14:51.
30. Miltgen G, Bonnin RA, Avril C, Benoit-Cattin T, Martak D, Leclaire A, et al. Outbreak of IMI-1 carbapenemase-producing colistin-resistant *Enterobacter cloacae* on the French island of Mayotte (Indian Ocean). *International journal of antimicrobial agents.* 2018;52(3):416-20.
31. Norgan AP, Freese JM, Tuin PM, Cunningham SA, Jeraldo PR, Patel R. Carbapenem- and Colistin-Resistant *Enterobacter cloacae* from Delta, Colorado, in 2015. *Antimicrob Agents Chemother.* 2016;60(5):3141-4.
32. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. <https://clsi.org/>: Clinical and Laboratory Standards Institute; 2018. p. Wayne, PA.
33. Li XZ, Plesiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. *Clin Microbiol Rev.* 2015;28(2):337-418.
34. Eguchi Y, Oshima T, Mori H, Aono R, Yamamoto K, Ishihama A, et al. Transcriptional regulation of drug efflux genes by EvgAS, a two-component system in *Escherichia coli*. *Microbiology.* 2003;149(Pt 10):2819-28.
35. Zhang A, Rosner JL, Martin RG. Transcriptional activation by MarA, SoxS and Rob of two tolC promoters using one binding site: a complex promoter configuration for tolC in *Escherichia coli*. *Mol Microbiol.* 2008;69(6):1450-5.
36. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017. <http://www.eucast.org>: The European Committee on Antimicrobial Susceptibility Testing; 2017.

37. Costa SS, Falcao C, Viveiros M, Machado D, Martins M, Melo-Cristino J, et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of *Staphylococcus aureus*. BMC microbiology. 2011;11:241.
38. Hankins JV, Madsen JA, Needham BD, Brodbelt JS, Trent MS. The outer membrane of Gram-negative bacteria: lipid A isolation and characterization. Methods in molecular biology (Clifton, NJ). 2013;966:239-58.

Figures

Strains	Carbapenem resistance									Colistin resistance				Efflux inhibitors assay			
	mCIM	<i>bla</i> _{KPC-2}	<i>bla</i> _{NDM-1}	<i>ampC</i>	<i>bla</i> _{SHV}	<i>bla</i> _{TEM}	<i>bla</i> _{CTX-M13}	<i>bla</i> _{CTX-M9}	<i>bla</i> _{CTX-M14}	<i>mcr-4.3</i>	<i>ecr</i>	-pETN	-L-Ara4N	ETP	ETP+CCCP	COL	COL+CCCP
Y541													2	2	8	0.125	
CG175													>128	>128	>64	0.06	
CG648													4	2	4	0.06	
CG737													4	2	>64	0.125	
CG741													4	2	64	0.125	
CG701													2	1	>64	0.125	
CG864													8	8	>64	0.125	
CG884													2	2	32	0.125	
CG934													2	2	>64	0.125	
CG1038													2	2	4	0.06	
CG1048													4	4	32	0.5	
CG1050													2	2	16	0.25	
CG1051													4	4	>64	0.25	
CG1249													16	16	>64	1	
CG1400													2	2	>64	0.125	
CG1479													128	64	>64	0.125	
CG1506													4	2	>64	0.25	
CG1574													8	4	>64	0.125	
CG1819													32	32	>64	0.125	

Figure 1

Results of resistance-related mechanisms of 19 carbapenems and colistin co-resistant ECC strains. The black squares in the figure represent positive results, and the gray squares represent negative results. And the unit of MIC values in the efflux inhibitors assay is $\mu\text{g/mL}$. mCIM, modified carbapenem inactivation methods; -pETN, phosphoethanolamine; -L-Ara4N, 4-amino-4-deoxy-L-arabinose; CCCP, carbonyl cyanide m-chlorophenylhydrazone; ETP, ertapenem; COL, colistin.





Figure 2

Relative expression of outer membrane protein gene *ompC*/*OmpF* and efflux pump protein gene *acrA*/*acrB*. (A) Expression of *ompC* and *OmpF*; (B) expression of *acrA* and *acrB*. CG37 is a clinical strain susceptible to carbapenem and colistin and ATCC700323 is the reference strain.




Figure 3

Results of MALDI-TOF mass spectrometry of lipid A. There are 4 different types of MS profile as shown by (A)(B)(C)(D). The black labeled ion peak is the original peak or modified peak not related to colistin resistance, and the red labeled ion peak is the modified peak related to colistin resistance.




Figure 4

Lipid A structures with corresponding m/z values found in ECC isolates.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TableS1.docx](#)
- [TableS2.docx](#)